Erschienen in:
01.05.2015 | Original Article
Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation
verfasst von:
Miki Sato, Shinichi Kako, Kana Matsumoto, Kumi Oshima, Yu Akahoshi, Hirofumi Nakano, Tomotaka Ugai, Ryoko Yamasaki, Hidenori Wada, Yuko Ishihara, Kana Sakamoto, Koji Kawamura, Masahiro Ashizawa, Kiriko Terasako-Saito, Shun-ichi Kimura, Hideki Nakasone, Misato Kikuchi, Aki Tanihara, Rie Yamazaki, Yukie Tanaka, Junya Kanda, Junji Nishida, Kunihiko Morita, Yoshinobu Kanda
Erschienen in:
International Journal of Hematology
|
Ausgabe 5/2015
Einloggen, um Zugang zu erhalten
Abstract
In Japan, intravenous busulfan (ivBu) is usually given four times per day as an infusion at 0.8 mg/kg over 2 h. However, as this requires a midnight administration, a once-daily infusion of ivBu at 3.2 mg/kg over 3 h has been investigated as a more convenient and safer method. In this study, 20 Japanese patients received once-daily ivBu in conditioning regimens before allogeneic hematopoietic stem cell transplantation (HSCT), and blood samples were obtained just before, and 3, 3.5, 5, 7, 10, and 24 h after the initiation of ivBu infusion. The outcomes of HSCT were evaluated prospectively. The median area under the plasma concentration versus time curve (AUC) of Bu was 5272 μmol × min/L (range 3491–6284 μmol × min/L), and was similar to those in previous once-daily ivBu studies and to the estimated daily AUC in previous 4-times-daily ivBu studies. All of the patients but two, who died early due to infection, achieved neutrophil engraftment at a median of 25 days after transplantation. No patient was diagnosed with veno-occlusive disease according to the criteria established by Jones. No regimen-related toxicity was significantly associated with AUC. In conclusion, once-daily administration of ivBu has a stable pharmacokinetic profile, and was safely performed in Japanese patients.